U.S. Biotech Stock News

In early March 2026, Astera Labs drew wider attention as market commentators praised its fundamentals, institutional investors disclosed new positions, and options activity highlighted heightened investor interest in its AI-focused data center connectivity solutions. Behind the headlines, the spotlight on Astera Labs’ role in easing data center bottlenecks for heterogeneous AI computing underscores how central interconnect technologies have become to modern cloud infrastructure. We’ll now...

If you are wondering whether Corteva's current share price really reflects its long term potential, this article walks through the key numbers that matter for value focused investors. Corteva's share price recently closed at US$78.30, with returns of 7.9% over the last 30 days and 31.3% over the past year, even though the last 7 days saw a 2.8% decline. Recent coverage around Corteva has centered on its position in the agricultural inputs space and how investors are weighing its role in...

Recent performance snapshot for Northrop Grumman (NOC) With no single headline event driving attention today, interest in Northrop Grumman (NOC) centers on how its recent share performance and current earnings profile fit into a broader, long term investment view. Over the past week the stock shows a 2.7% decline, following a 1 day move of about 1.2% lower, while the past month return is about 5.4% and the past 3 months about 35.7%. On a longer horizon, Northrop Grumman reports a year to date...

Edwards Lifesciences recently appointed Niranjan Pai, formerly a director at APCO with prior experience at Ernst & Young, as Director-Government Affairs, while also reshaping its portfolio by divesting its critical care unit to sharpen focus on structural heart therapies. This combination of leadership change and tighter focus on areas such as asymptomatic aortic stenosis and structural heart failure could influence how the company executes on its pipeline in transcatheter mitral and...

Collegium Pharmaceutical stock performance snapshot Collegium Pharmaceutical (COLL) has drawn investor attention after recent trading, with the share price at $37.27 and short term returns under pressure, including a 10.4% decline over the past week. The stock has also seen a 21.7% decline over the past month and 20.8% over the past 3 months, even as the company reports annual revenue of $780.567m and net income of $62.87m. See our latest analysis for Collegium Pharmaceutical. While the...

If you are wondering whether Seagate Technology Holdings at around US$374.33 still offers value after a strong run, you are not alone. The stock has seen a 1.4% decline over the last 7 days and a 12.8% decline over the last 30 days, while its year to date return is 30.2% and the 1 year return is 341.6%, with a very large 3 year return and a very large 5 year return. These moves sit against a backdrop of ongoing interest in storage hardware and data infrastructure companies, with investors...

In February 2026, Life Time Group Holdings, Inc. reported higher fourth-quarter and full-year 2025 revenue and net income versus 2024, reiterated its 2026 revenue and earnings guidance, and authorized a US$500 million share repurchase program with no expiration date. The combination of stronger profitability and a sizable, open-ended buyback plan highlights management’s confidence in the company’s cash generation and capital allocation priorities. Next, we’ll examine how this substantial...

Home Depot (NYSE:HD) reported a major loss prevention incident involving a fraudulent return scheme linked to more than 1,700 transactions across multiple stores. The same case also included a threatening incident directed at loss prevention staff, raising concerns about employee safety and store level enforcement. The incident represents a material operational and reputational event for the retailer, with potential implications for internal controls, fraud detection, and theft prevention...

O-I Glass recently reported that the first quarter of 2026 was tougher than expected, citing softer European demand, supply chain costs from factory closures, and pricing pressure in wine, even as it kept its full-year outlook unchanged. At the same time, the company nearly doubled adjusted earnings to US$1.60 per share in 2025, lifted by US$300 million of Fit to Win savings, and raised its three-year efficiency target to at least US$750 million, underscoring management’s focus on...

Why Realty Income is on investors’ radar Realty Income (O) is drawing fresh attention after recent share price moves, with the stock roughly flat over the past day, softer over the past week, yet positive over the past month and past 3 months. See our latest analysis for Realty Income. Looking beyond the recent pullback, Realty Income’s 30-day share price return of 2.70% and 90-day share price return of 13.83% sit alongside a 1-year total shareholder return of 17.33%. This indicates that...

If you are wondering whether WisdomTree still offers good value after its recent run, or if most of the easy gains are behind it, this article will walk you through what the current price might be implying. The stock last closed at US$16.59, with returns of 5.4% over 30 days, 32.6% year to date, and 99.7% over the past year. This raises fair questions about both upside potential and changing risk. Recent attention on exchange traded product providers, including flows into thematic and income...

AbCellera Biologics (ABCL) is back in focus after releasing full year 2025 results, reporting revenue of US$75.13 million compared with US$28.83 million a year earlier and a net loss of US$146.41 million compared with US$162.86 million. See our latest analysis for AbCellera Biologics. AbCellera Biologics’ latest earnings drop comes after a mixed period for investors, with a 1-month share price return of 11.39% but a 3-year total shareholder return decline of 52.56% and a 5-year total...

If you are wondering whether ImmunityBio's current share price really reflects its potential, you are not alone. This article focuses on what the numbers suggest about value rather than short term excitement. The stock closed at US$8.45 most recently, with returns of 39.7% over 30 days, 318.3% year to date and 190.4% over 1 year, although the last 7 days saw a 19.1% decline and the 5 year return sits at a 72.6% loss. These swings have come alongside ongoing interest in ImmunityBio's pipeline...

Himax Technologies recently participated in Embedded World 2026 in Nuremberg, Germany, showcasing its WiseEye ultralow power endpoint AI, automotive display IC portfolio, and advanced optical solutions through live demonstrations. A standout theme was the WiseEye-based WiseGuard and PalmVein modules, which pair milliwatt-level AI sensing with contactless biometric security to enable long-life, low-power applications across smart home, access control, and industrial devices. We’ll now examine...

Q4 2025 earnings shift focus back to Crane’s top line Crane (CR) is back in the spotlight after reporting higher sales and earnings for Q4 and full year 2025, ending a multi year revenue decline and prompting analysts to revisit their growth assumptions. See our latest analysis for Crane. Crane’s recent Q4 update lands after a strong run for long term holders, with a 1 year total shareholder return of 26.62% and a 5 year total shareholder return of 231.46%. At the same time, the 7 day share...

What Delta Air Lines stock’s recent pullback may mean for investors Delta Air Lines (DAL) shares have retreated in the past month and past 3 months, even as the company reports annual revenue of about US$63.4b and net income of US$5.0b. See our latest analysis for Delta Air Lines. Despite the recent weakness, with a 30 day share price return of 19.6% and a 90 day share price return of 10.13%, longer term performance has been stronger. This is highlighted by a 1 year total shareholder return...

Early March, the FDA approved Bristol-Myers Squibb’s Sotyktu for adults with active psoriatic arthritis, the first TYK2 inhibitor cleared for this use following Phase 3 trials. In a separate early March update, oral mezigdomide showed significant progression free survival benefit in a Phase 3 trial in relapsed or refractory multiple myeloma. Bristol-Myers Squibb, NYSE:BMY, is adding fresh clinical momentum to a portfolio that already spans immunology and cancer. The stock last closed at...

On March 5, 2026, Waystar announced an expanded collaboration with Google Cloud to integrate Gemini models and data infrastructure more deeply into its AI-powered healthcare revenue cycle platform, aiming to support more autonomous, hyperscale deployment across complex billing and claims workflows. This move brings together financial and clinical intelligence from billions of transactions, positioning Waystar to develop new agentic AI use cases across the full patient and claims...

In early March 2026, Lantronix Inc. expanded its embedded compute platform with new MediaTek Genio-based System-on-Module solutions and signed a European distribution partnership with Milan-based Melchioni Electronics to broaden sales and technical support across key EU markets. Together, the MediaTek-powered Edge AI modules and Melchioni’s regional reach materially widen Lantronix’s addressable markets, design-win potential and supply resilience across industrial and commercial IoT...

Shopify (NasdaqGS:SHOP) and Klaviyo announced a major product integration focused on global e-commerce personalization and localization. The integration introduces Locale Aware Catalogs, designed to help brands manage translated content, regional pricing, and regional product catalogues within a unified workflow. This update targets operational hurdles for international expansion faced by Shopify’s global merchants using Klaviyo’s marketing automation tools. For you as an investor or...

Palantir Technologies stock: recent performance snapshot Palantir Technologies (PLTR) has drawn attention after a mixed stretch for the share price, with a 15.1% gain over the past month contrasting with a 14.0% decline over the past 3 months. For investors tracking the longer story, the stock shows a 6.8% decline year to date, while the 1 year total return sits at 104.8%, alongside multi year total returns that remain very large. See our latest analysis for Palantir Technologies. Looking...

Full year 2025 earnings reset the backdrop for Talen Energy stock Talen Energy (TLN) shares are trading against a fresh earnings backdrop after the company reported full year 2025 results, with higher reported sales but a shift from profit to a net loss. See our latest analysis for Talen Energy. The latest full year results arrived after a mixed period for the stock, with a 1 day share price return of 4.54% but a year to date share price decline of 15.53%. At the same time, the 1 year total...

Why AvePoint’s AgentPulse launch matters for AVPT shareholders AvePoint (AVPT) has put its AgentPulse Command Center into general availability, extending AI agent monitoring and cost controls across Microsoft 365 and Google Cloud. This directly targets current concerns around shadow AI, data protection, and usage spend. See our latest analysis for AvePoint. The latest AgentPulse launch comes after a strong fourth quarter earnings report and fresh 2026 revenue guidance. However, AvePoint’s 90...

If you are trying to figure out whether USA Rare Earth's current share price makes sense, this article walks through what the numbers are actually saying about value. The stock closed at US$18.71, with a 10.3% decline over the last 7 days and a 14.3% decline over the last 30 days, while still showing a 32.2% gain year to date and a 71.5% gain over the last 12 months. Recent share price moves are happening against a backdrop of ongoing attention on rare earth supply security and interest in...